Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma

[1]Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015; 100: 55-62.ChindrisAMCaslerJDBernetVJRiveraMThomasCKachergusJMet al.Clinical and molecular features of Hürthle cell carcinoma of the thyroidJ Clin Endocrinol Metab2015100556210.1210/jc.2014-1634Search in Google Scholar

[2]Cannon J. The significance of hurthle cells in thyroid disease. Oncologist 2011; 16: 1380-7.CannonJThe significance of hurthle cells in thyroid diseaseOncologist2011161380710.1634/theoncologist.2010-0253Search in Google Scholar

[3]Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M. Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta Otorhinolaryngol ital 2009; 29: 305-11.BarnabeiAFerrettiEBaldelliRProcacciniASprianoGAppetecchiaMHurthle cell tumours of the thyroid. Personal experience and review of the literatureActa Otorhinolaryngol ital20092930511Search in Google Scholar

[4]Petric R, Gazic B, Besic N. Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer 2014; 14: 777.PetricRGazicBBesicNPrognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experienceBMC Cancer20141477710.1186/1471-2407-14-777Search in Google Scholar

[5]Baloch ZW, LiVolsi VA. Our approach to follicular-patterned lesions of the thyroid. J Clin Pathol 2007; 60: 244-50.BalochZWLiVolsiVAOur approach to follicular-patterned lesions of the thyroidJ Clin Pathol2007602445010.1136/jcp.2006.038604Search in Google Scholar

[6]Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989; 63: 908-11.HedingerCWilliamsEDSobinLHThe WHO histological classification of thyroid tumors: a commentary on the second editionCancer1989639081110.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-ISearch in Google Scholar

[7]Rosai J. Tumors of the thyroid gland. In: Rosai J, Carcangiu ML, editors. Atlas of Tumor Pathology. Washington: Armed Forces Institute of Pathology; 1992. p. 31-50.RosaiJTumors of the thyroid glandRosaiJCarcangiuMLAtlas of Tumor PathologyWashingtonArmed Forces Institute of Pathology19923150Search in Google Scholar

[8]Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002; 26: 41-4.BalochZWFleisherSLiVolsiVAGuptaPKDiagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytologyDiagn Cytopathol20022641410.1002/dc.10043Search in Google Scholar

[9]Baloch ZW, LiVolsi VA. Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab 2008; 22: 929-39.BalochZWLiVolsiVAFine-needle aspiration of the thyroid: today and tomorrowBest Pract Res Clin Endocrinol Metab2008229293910.1016/j.beem.2008.09.011Search in Google Scholar

[10]Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N. Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol 2010; 101: 582-6.StrazisarBPetricRSesekMZgajnarJHocevarMBesicNPredictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid glandJ Surg Oncol2010101582610.1002/jso.21526Search in Google Scholar

[11]Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/ suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014; 120: 3627-34.NikiforovYECartySEChioseaSICoyneCDuvvuriUFerrisRLet al.Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/ suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assayCancer201412036273410.1002/cncr.29038Search in Google Scholar

[12]Sobrinho-Simões M, Máximo V, Castro IV, Fonseca E, Soares P, Garcia-Rostan G, et al. Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol 2005; 13: 29-35.Sobrinho-SimõesMMáximoVCastroIVFonsecaESoaresPGarcia-RostanGet al.Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significanceInt J Surg Pathol200513293510.1177/106689690501300104Search in Google Scholar

[13]Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol 2004; 57: 225-32.AsaSLMy approach to oncocytic tumours of the thyroidJ Clin Pathol2004572253210.1136/jcp.2003.008474177024614990587Search in Google Scholar

[14]Villanueva I, Alva-Sánchez C, Pacheco-Rosado J. The role of thyroid hormones as inductors of oxidative stress and neurodegeneration. Oxid Med Cell Longev 2013; 2013: 218145.VillanuevaIAlva-SánchezCPacheco-RosadoJThe role of thyroid hormones as inductors of oxidative stress and neurodegenerationOxid Med Cell Longev2013201321814510.1155/2013/218145387209824386502Search in Google Scholar

[15]Xing M. Oxidative stress: a new risk factor for thyroid cancer. Endocr Relat Cancer 2012; 19: C7-11.XingMOxidative stress: a new risk factor for thyroid cancerEndocr Relat Cancer201219C71110.1530/ERC-11-0360377892022143496Search in Google Scholar

[16]Karbownik-Lewinska M, Kokoszko-Bilska A. Oxidative damage to macromolecules in the thyroid - experimental evidence. Thyroid Res 2012; 5: 25.Karbownik-LewinskaMKokoszko-BilskaAOxidative damage to macromolecules in the thyroid - experimental evidenceThyroid Res201252510.1530/endoabs.35.S3.3Search in Google Scholar

[17]Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010; 38: 96-109.KlaunigJEKamendulisLMHocevarBAOxidative stress and oxidative damage in carcinogenesisToxicol Pathol2010389610910.1177/019262330935645320019356Search in Google Scholar

[18]Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S, et al. Oxidative stress and its significant roles in neurodegenerative diseases and cancer. Int J Mol Sci 2014; 16: 193-217.ThananROikawaSHirakuYOhnishiSMaNPinlaorSet al.Oxidative stress and its significant roles in neurodegenerative diseases and cancerInt J Mol Sci20141619321710.3390/ijms16010193430724325547488Search in Google Scholar

[19]Young O, Crotty T, O’Connell R, O’Sullivan J, Curran AJ. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck 2010; 32: 750-6.YoungOCrottyTO’ConnellRO’SullivanJCurranAJLevels of oxidative damage and lipid peroxidation in thyroid neoplasiaHead Neck201032750610.1002/hed.2124719998441Search in Google Scholar

[20]Wang D, Feng JF, Zeng P, Yang YH, Luo J, Yang YW. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocr Relat Cancer 2011; 18: 773-82.WangDFengJFZengPYangYHLuoJYangYWTotal oxidant/antioxidant status in sera of patients with thyroid cancersEndocr Relat Cancer2011187738210.1530/ERC-11-0230323011222002574Search in Google Scholar

[21]Marcocci C, Leo M, Altea MA. Oxidative stress in Graves disease. Eur Thyroid J 2012; 1: 80-7.MarcocciCLeoMAlteaMAOxidative stress in Graves diseaseEur Thyroid J2012180710.1159/000337976382146924783001Search in Google Scholar

[22]Klubo-Gwiezdzinska J, Jensen K, Bauer A, Patel A, Costello J Jr, Burman KD, et al. The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress. J Endocrinol 2012; 214: 207-16.Klubo-GwiezdzinskaJJensenKBauerAPatelACostelloJJrBurmanKDet al.The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stressJ Endocrinol20122142071610.1530/JOE-12-0081608443722645299Search in Google Scholar

[23]Tabur S, Aksoy ŞN, Korkmaz H, Ozkaya M, Aksoy N, Akarsu E. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma. Tumour Biol 2015; 36: 2667-74.TaburSAksoyŞNKorkmazHOzkayaMAksoyNAkarsuEInvestigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinomaTumour Biol20153626677410.1007/s13277-014-2889-6Search in Google Scholar

[24]Lassoued S, Mseddi M, Mnif F, Abid M, Guermazi F, Masmoudi H, et al. A comparative study of the oxidative profile in Graves’ disease, Hashimoto’s thyroiditis, and papillary thyroid cancer. Biol Trace Elem Res 2010; 138: 107-15.LassouedSMseddiMMnifFAbidMGuermaziFMasmoudiHet al.A comparative study of the oxidative profile in Graves’ disease, Hashimoto’s thyroiditis, and papillary thyroid cancerBiol Trace Elem Res20101381071510.1007/s12011-010-8625-1Search in Google Scholar

[25]Karger S, Krause K, Engelhardt C, Weidinger C, Gimm O, Dralle H, et al. Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumours. J Mol Endocrinol 2012; 48: 193-202.KargerSKrauseKEngelhardtCWeidingerCGimmODralleHet al.Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumoursJ Mol Endocrinol20124819320210.1530/JME-11-0119Search in Google Scholar

[26]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.CooperDSDohertyGMHaugenBRKloosRTLeeSLMandelSJet al.American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200919116721410.1089/thy.2009.0110Search in Google Scholar

[27]Jazbec J, Aplenc R, Dolzan V, Debeljak M, Jereb B. GST polymorphisms and occurrence of second neoplasms after treatment of childhood leukemia. Leukemia 2003; 17: 2540-2.JazbecJAplencRDolzanVDebeljakMJerebBGST polymorphisms and occurrence of second neoplasms after treatment of childhood leukemiaLeukemia2003172540210.1038/sj.leu.2403164Search in Google Scholar

[28]Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-9.TregouetDAGarelleVA new JAVA interface implementation of THESIAS: testing haplotype effects in association studiesBioinformatics2007231038910.1093/bioinformatics/btm058Search in Google Scholar

[29]Erčulj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolžan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 2012; 22: 58-68.ErčuljNKovacVHmeljakJFrankoADodic-FikfakMDolžanVThe influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesotheliomaPharmacogenet Genomics201222586810.1097/FPC.0b013e32834e3572Search in Google Scholar

[30]Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hurthle cell tumors of the thyroid gland. Cancer 1991; 68: 1944-53.CarcangiuMLBianchiSSavinoDVoynickIMRosaiJFollicular Hurthle cell tumors of the thyroid glandCancer19916819445310.1002/1097-0142(19911101)68:9<1944::AID-CNCR2820680917>3.0.CO;2-ISearch in Google Scholar

[31]Elliott DD, Pitman MB, Bloom L, Faquin WC. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer 2006; 108: 102-9.ElliottDDPitmanMBBloomLFaquinWCFine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysisCancer2006108102910.1002/cncr.21716Search in Google Scholar

[32]Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer 2003; 97: 1186-94.Lopez-PenabadLChiuACHoffAOSchultzPGaztambideSOrdoñezNGet al.Prognostic factors in patients with Hürthle cell neoplasms of the thyroidCancer20039711869410.1002/cncr.11176Search in Google Scholar

[33]Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, et al. Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol 2008; 15: 2842-6.ZhangYWGreenblattDYRepplingerDBargrenAAdlerJTSippelRSet al.Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroidAnn Surg Oncol2008152842610.1245/s10434-008-0079-8Search in Google Scholar

[34]Forsberg L, Lyrenäs L, de Faire U, Morgenstern R. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 2001; 30: 500-5.ForsbergLLyrenäsLde FaireUMorgensternRA common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levelsFree Radic Biol Med200130500510.1016/S0891-5849(00)00487-1Search in Google Scholar

[35]Bastaki M, Huen K, Manzanillo P, Chande N, Chen C, Balmes JR, et al. Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics 2006; 16: 279-86.BastakiMHuenKManzanilloPChandeNChenCBalmesJRet al.Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humansPharmacogenet Genomics2006162798610.1097/01.fpc.0000199498.08725.9cSearch in Google Scholar

[36]Gavalas NG, Akhtar S, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH. Analysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligo. Biochem Biophys Res Commun 2006; 345: 1586-91.GavalasNGAkhtarSGawkrodgerDJWatsonPFWeetmanAPKempEHAnalysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligoBiochem Biophys Res Commun200634515869110.1016/j.bbrc.2006.05.063Search in Google Scholar

[37]Sadani GR, Nadkarni GD. Role of tissue antioxidant defence in thyroid cancers. Cancer Lett 1996; 109: 231-5.SadaniGRNadkarniGDRole of tissue antioxidant defence in thyroid cancersCancer Lett1996109231510.1016/S0304-3835(96)04484-9Search in Google Scholar

[38]Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, et al. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am J Epidemiol 2005; 162: 943-52.AhnJGammonMDSantellaRMGaudetMMBrittonJATeitelbaumSLet al.Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement useAm J Epidemiol20051629435210.1093/aje/kwi30616192345Search in Google Scholar

[39]Ahn J, Nowell S, McCann SE, Yu J, Carter L, Lang NP, et al. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev 2006; 15: 1217-22.AhnJNowellSMcCannSEYuJCarterLLangNPet al.Associations between catalase phenotype and genotype: modification by epidemiologic factorsCancer Epidemiol Biomarkers Prev20061512172210.1158/1055-9965.EPI-06-010416775184Search in Google Scholar

[40]Chistiakov DA, Savost’anov KV, Turakulov RI, Titovich EV, Zilberman LI, Kuraeva TL, et al. A new type 1 diabetes susceptibility locus containing the catalase gene (chromosome 11p13) in a Russian population. Diabetes Metab Res Rev 2004; 20: 219-24.ChistiakovDASavost’anovKVTurakulovRITitovichEVZilbermanLIKuraevaTLet al.A new type 1 diabetes susceptibility locus containing the catalase gene (chromosome 11p13) in a Russian populationDiabetes Metab Res Rev2004202192410.1002/dmrr.44215133753Search in Google Scholar

[41]Akyol O, Yanik M, Elyas H, Namli M, Canatan H, Akin H, et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 123-31.AkyolOYanikMElyasHNamliMCanatanHAkinHet al.Association between Ala-9Val polymorphism of Mn-SOD gene and schizophreniaProg Neuropsychopharmacol Biol Psychiatry2005291233110.1016/j.pnpbp.2004.10.01415610954Search in Google Scholar

[42]Gałecki P, Pietras T, Szemraj J. Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland. Psychiatr Pol 2006; 40: 937-48.GałeckiPPietrasTSzemrajJManganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central PolandPsychiatr Pol20064093748Search in Google Scholar

[43]Zai CC, Tiwari AK, Basile V, de Luca V, Müller DJ, Voineskos AN, et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 50-6.ZaiCCTiwariAKBasileVde LucaVMüllerDJVoineskosANet al.Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genesProg Neuropsychopharmacol Biol Psychiatry20103450610.1016/j.pnpbp.2009.09.02019778569Search in Google Scholar

[44]Boškovic M, Vovk T, Saje M, Goricar K, Dolžan V, Kores Plesnicar B, et al. Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia. Neurochem Res 2013; 38: 433-42.BoškovicMVovkTSajeMGoricarKDolžanVKores PlesnicarBet al.Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophreniaNeurochem Res2013384334210.1007/s11064-012-0937-423212700Search in Google Scholar

[45]Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003; 13: 145-57.SuttonAKhouryHPrip-BuusCCepanecCPessayreDDegoulFThe Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondriaPharmacogenetics2003131455710.1097/00008571-200303000-00004Search in Google Scholar

[46]Nishida S, Akai F, Iwasaki H, Hosokawa K, Kusunoki T, Suzuki K, et al. Manganese superoxide dismutase content and localization in human thyroid tumours. J Pathol 1993; 169: 341-5.NishidaSAkaiFIwasakiHHosokawaKKusunokiTSuzukiKet al.Manganese superoxide dismutase content and localization in human thyroid tumoursJ Pathol1993169341510.1002/path.17116903118492227Search in Google Scholar

[47]Akinci M, Kosova F, Cetin B, Sepici A, Altan N, Aslan S, et al. Oxidant/antioxidant balance in patients with thyroid cancer. Acta Cir Bras 2008; 23: 551-4.AkinciMKosovaFCetinBSepiciAAltanNAslanSet al.Oxidant/antioxidant balance in patients with thyroid cancerActa Cir Bras200823551410.1590/S0102-86502008000600013Search in Google Scholar

[48]Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, et al. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J Endocrinol Invest 2005; 28: 137-44.RussoDBiscaACelanoMTalamoFArturiFScipioniAet al.Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cellsJ Endocrinol Invest2005281374410.1007/BF0334535615887859Search in Google Scholar

[49]Li J, Long J, Hu Y, Tan A, Guo X, Zhang S. Glutathione S-transferase M1, T1, and P1 polymorphisms and thyroid cancer risk: a meta-analysis. Cancer Epidemiol 2012; 36: e333-40.LiJLongJHuYTanAGuoXZhangSGlutathione S-transferase M1, T1, and P1 polymorphisms and thyroid cancer risk: a meta-analysisCancer Epidemiol201236e3334010.1016/j.canep.2012.06.00222765906Search in Google Scholar

[50]Stankov K, Landi S, Gioia-Patricola L, Bonora E, Volante M, Papotti M, et al. GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients. Cancer Lett 2006; 240: 76-82.StankovKLandiSGioia-PatricolaLBonoraEVolanteMPapottiMet al.GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patientsCancer Lett2006240768210.1016/j.canlet.2005.08.01716427734Search in Google Scholar

[51]Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-12.Ali-OsmanFAkandeOAntounGMaoJXBuolamwiniJMolecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteinsJ Biol Chem1997272100041210.1074/jbc.272.15.100049092542Search in Google Scholar

[52]Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-80.WatsonMAStewartRKSmithGBMasseyTEBellDAHuman glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distributionCarcinogenesis1998192758010.1093/carcin/19.2.2759498276Search in Google Scholar

[53]Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-66.HayesJDStrangeRCGlutathione S-transferase polymorphisms and their biological consequencesPharmacology2000611546610.1159/00002839610971201Search in Google Scholar

[54]Siraj AK, Ibrahim M, Al-Rasheed M, Abubaker J, Bu R, Siddiqui SU, et al. Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in the Middle Eastern population. BMC Med Genet 2008; 9: 61.SirajAKIbrahimMAl-RasheedMAbubakerJBuRSiddiquiSUet al.Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in the Middle Eastern populationBMC Med Genet200896110.1186/1471-2350-9-61Search in Google Scholar

[55]Ho T, Zhao C, Zheng R, Liu Z, Wei Q, Sturgis EM. Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Arch Otolaryngol Head Neck Surg 2006; 132: 756-61.HoTZhaoCZhengRLiuZWeiQSturgisEMGlutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysisArch Otolaryngol Head Neck Surg20061327566110.1001/archotol.132.7.756Search in Google Scholar

[56]Granja F, Morari J, Morari EC, Correa LA, Assumpção LV, Ward LS. GST profiling may be useful in the screening for thyroid nodule malignancy. Cancer Lett 2004; 209: 129-37.GranjaFMorariJMorariECCorreaLAAssumpçãoLVWardLSGST profiling may be useful in the screening for thyroid nodule malignancyCancer Lett20042091293710.1016/j.canlet.2003.12.013Search in Google Scholar

[57]Lemos MC, Coutinho E, Gomes L, Carrilho F, Rodrigues F, Regateiro FJ, et al. Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancer. J Endocrinol Invest 2008; 31: 542-5.LemosMCCoutinhoEGomesLCarrilhoFRodriguesFRegateiroFJet al.Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancerJ Endocrinol Invest200831542510.1007/BF03346405Search in Google Scholar

[58]Gaspar J, Rodrigues S, Gil OM, Manita I, Ferreira TC, Limbert E, et al. Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet Cytogenet 2004; 151: 60-7.GasparJRodriguesSGilOMManitaIFerreiraTCLimbertEet al.Combined effects of glutathione S-transferase polymorphisms and thyroid cancer riskCancer Genet Cytogenet200415160710.1016/j.cancergencyto.2003.09.018Search in Google Scholar

[59]Gonçalves AJ, Carvalho LH, Serdeira K, Nakai MY, Malavasi TR. Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells. Sao Paulo Med J 2007; 125: 289-91.GonçalvesAJCarvalhoLHSerdeiraKNakaiMYMalavasiTRComparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cellsSao Paulo Med J20071252899110.1590/S1516-31802007000500008Search in Google Scholar

[60]Kweon SS, Shin MH, Kim HN, Kim SH, Kang HC. Polymorphisms of methylenetetrahydrofolate reductase and glutathione S-transferase are not associated with the risk of papillary thyroid cancer in Korean population. Mol Biol Rep 2014; 41: 3793-9.KweonSSShinMHKimHNKimSHKangHCPolymorphisms of methylenetetrahydrofolate reductase and glutathione S-transferase are not associated with the risk of papillary thyroid cancer in Korean populationMol Biol Rep2014413793910.1007/s11033-014-3245-zSearch in Google Scholar

[61]Hernández A, Céspedes W, Xamena N, Surrallés J, Creus A, Galofré P, et al. Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett 2003; 190: 37-44.HernándezACéspedesWXamenaNSurrallésJCreusAGalofréPet al.Glutathione S-transferase polymorphisms in thyroid cancer patientsCancer Lett2003190374410.1016/S0304-3835(02)00580-3Search in Google Scholar

[62]Vodusek AL, Goricar K, Gazic B, Dolzan V, Jazbec J. Antioxidant defence-related genetic variants are not associated with higher risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescence. Radiol Oncol 2016; 50: 80-6.VodusekALGoricarKGazicBDolzanVJazbecJAntioxidant defence-related genetic variants are not associated with higher risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescenceRadiol Oncol20165080610.1515/raon-2015-0026482534227069453Search in Google Scholar

[63]Méplan C, Dragsted LO, Ravn-Haren G, Tjønneland A, Vogel U, Hesketh J. Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer risk. PLoS One 2013; 8: e73316.MéplanCDragstedLORavn-HarenGTjønnelandAVogelUHeskethJAssociation between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer riskPLoS One20138e7331610.1371/journal.pone.0073316376927224039907Search in Google Scholar

[64]Takano T, Hasegawa Y, Matsuzuka F, Miyauchi A, Yoshida H, Higashiyama T, et al. Gene expression profiles in thyroid carcinomas. Br J Cancer 2000; 83: 1495-502.TakanoTHasegawaYMatsuzukaFMiyauchiAYoshidaHHigashiyamaTet al.Gene expression profiles in thyroid carcinomasBr J Cancer200083149550210.1054/bjoc.2000.1483Search in Google Scholar

[65]Hasegawa Y, Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, et al. Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinoma. Cancer Lett 2002; 182: 69-74.HasegawaYTakanoTMiyauchiAMatsuzukaFYoshidaHKumaKet al.Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinomaCancer Lett2002182697410.1016/S0304-3835(02)00069-1Search in Google Scholar

[66]Chen J, Cao Q, Qin C, Shao P, Wu Y, Wang M, et al. GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from metaanalysis. J Cancer Res Clin Oncol 2011; 137: 1553-61.ChenJCaoQQinCShaoPWuYWangMet al.GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from metaanalysisJ Cancer Res Clin Oncol201113715536110.1007/s00432-011-1033-x21842217Search in Google Scholar

[67]Brigelius-Flohé R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 2009; 1790: 1555-68.Brigelius-FlohéRKippAGlutathione peroxidases in different stages of carcinogenesisBiochim Biophys Acta2009179015556810.1016/j.bbagen.2009.03.00619289149Search in Google Scholar

[68]Yuzhalin AE, Kutikhin AG. Inherited variations in the SOD and GPX gene families and cancer risk. Free Radic Res 2012; 46: 581-99.YuzhalinAEKutikhinAGInherited variations in the SOD and GPX gene families and cancer riskFree Radic Res2012465819910.3109/10715762.2012.65851522257147Search in Google Scholar

[69]Zhao H, Liang D, Grossman HB, Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology 2005; 66: 769-???.ZhaoHLiangDGrossmanHBWuXGlutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancerUrology200566769-???10.1016/j.urology.2005.04.03316230136Search in Google Scholar